Assessing VYVGARTTM Social Media Data in generalized Myasthenia Gravis to Understand Patient, Caregiver, and HCP Sentiment

<u>Tom Hughes¹</u>, Albert Whangbo², Swati Shukla³, Aditya Batra³, Kaushik Bhattacharya⁴, Anshul Sharma³, Shreyas Jarmale⁴

¹argenx, Boston, MA, USA; ²ZS Associates, Durham, NC, USA; ³ZS Associates, Gurgaon, Haryana, India; ⁴ZS Associates, Bengaluru, Karnataka, India

INTRODUCTION


- VYVGART[™] (efgartigimod), approved in 2021, is a first-in-class intravenous neonatal fragment crystallizable receptor antagonist for the treatment of generalized Myasthenia Gravis (gMG), offering an alternative for patients beyond corticosteroids and broad immunosuppressants.^{1,2}
- Social media serves as a valuable complement to traditional data sources, capturing unfiltered and unprompted patient experiences and sentiments about treatments, quality of life (QoL), steroid use reduction, cost burdens, and insurance challenges.^{3,4}
- Evaluating social media content is crucial to gain deeper insights into the discussions, sentiments, and challenges expressed by patients, caregivers, and healthcare professionals (HCPs).
- This information regarding VYVGART and VYVGART Hytrulo would help improve care strategies for gMG patients and guide future research of gMG therapies.

OBJECTIVE

- To categorize and quantify the distribution of discussions and sentiment regarding VYVGART and VYVGART Hytrulo across patients, caregivers, and HCPs.
- To explore subtopics within these discussions and analyze their associated sentiments to understand the varied experiences and opinions across the three groups.


RESULTS

- Patient sentiment overall for VYVGART was positive (49%).
- Treatment experience was the most discussed topic among patients, while brand awareness was the predominant topic among HCPs (Figure 3).



METHODS

- discussions.



- gMG, generalized Myasthenia Gravis.

Treatment Ex			
U Positive	••	Ne	
Effectiveness			
Treatment options			
Treatment switch			
Side effects			
QoL			

Brand Awareness

Treatment consideration Knowledge sharing Seeking information and experiences

Access to Treatment Insurance Cost HCP approva

Treatment Support 🙂 Positive

Experience with HCPs. hospitals, clinics Support from manufacturers

100%. Therefore, topics and subtopics are not mutually exclusive. HCPs, Healthcare professionals; QoL, Quality of life.

• VYVGART, VYVGART Hytrulo, and gMG posts were identified from social media platforms including Reddit, Facebook, Instagram, and YouTube (Figure 1). • Data was collected using Brandwatch over a 38-month period removing irrelevant content to retain meaningful discussions (Figure 1). • All posts with keywords "VYVGART", "VYVGART Hytrulo", "VYVGART Vyvdura", or "efgartigimod", were in English language, related to clinical trials and were specific to gMG. • Posts were analyzed with ZS GenAI algorithms, removing irrelevant data and applying exclusion criteria to filter out inappropriate content, advertisements, or non-specific


*For platforms lacking location data, (Reddit, Facebook, Instagram, YouTube) posts are assumed to be US-based unless geographic details suggest otherwise. #using ZS GenAI algorithms with manual validation.


 Patients report positive experiences with VYVGART and VYVGART Hytrulo, emphasizing their high effectiveness, enhanced QoL, and enthusiasm about beginning treatment (Figure 4).

• Patients were enthusiastic about VYVGART as a promising new treatment for gMG (Figure 4).

- Figure 4. Insights into patient views (n=889) xperience n=593 egative 💀 Neutral 106 273 **55** 21 121 13 Number of posts n=402 、 🙂 Positive 🙁 Negative 💀 Neutral 135 110 3 2 108 Number of posts n=157 🙂 Positive 🙁 Negative 😐 Neutral Number of posts n=31 🙁 Negative 😐 Neutral 5 10 Number of posts A post can be tagged under multiple topics, subtopics and may carry multiple sentiments, leading to total counts exceeding
- Caregivers noted substantial improvements in symptoms and QoL with VYVGART, though some expressed concerns about side effects like pain. They actively shared treatment experiences and opinions on its cost (Figure 5).

Figure	5. Insights into a		
Treatment Experience			
🙂 Positive 🙁 Negative	• Neutral		
Effectiveness	3		
Treatment switch	2		
Steroid usage	1		
Treatment initiation			
QoL			
Side effects			
Infusion scheduling			
Į	ן 		
Brand Awarenes	S		
🙂 Positive 🙁 Negative	e 😐 Neutral		
Seeking information and experience			
Treatment consideration	n		
	N		
Access to Treatment			
🙂 Positive 🙁 Negative	• Neutral		
Eligibility criteria			
Cost	1		
Treatment Suppo	ort		
🙂 Positive 🙁 Negative	• Neutral		
A post can be tagged under multi exceeding 100%. Therefore, topic QoL, Quality of life.			





• Relevant posts were classified into four distinct topics: brand awareness, access to treatment, treatment experience, and treatment support (Figure 1).

• A total of 4214 global social media posts were identified. Of these 1046 were found to be relevant: Patients (n=889 posts; 85%), Caregivers (n=29 posts; 3%), and HCPs (n=128 posts; 12%) (Figure 2). • The majority of posts were for VYVGART (1015 posts) with a smaller number of posts for VYVGART